European Journal of Nuclear Medicine and Molecular Imaging

, Volume 32, Issue 9, pp 1129–1129

Visualisation of a somatostatin receptor-expressing tumour with 67Ga-DOTATOC SPECT


    • Institut für KernchemieUniversität Mainz
  • P. Aschoff
    • Klinik für NuklearmedizinKlinikum Stuttgart—Katharinenhospital
  • D. Filosofov
    • Joint Institute of Nuclear Research, LNP
  • M. Jahn
    • Institut für KernchemieUniversität Mainz
  • M. Jennewein
    • Institut für KernchemieUniversität Mainz
  • H.-J. Adrian
    • Klinik für NuklearmedizinKlinikum Stuttgart—Katharinenhospital
  • H. Bihl
    • Klinik für NuklearmedizinKlinikum Stuttgart—Katharinenhospital
  • F. Rösch
    • Institut für KernchemieUniversität Mainz
Image of the Month

DOI: 10.1007/s00259-005-1864-2

Cite this article as:
Zhernosekov, K., Aschoff, P., Filosofov, D. et al. Eur J Nucl Med Mol Imaging (2005) 32: 1129. doi:10.1007/s00259-005-1864-2

In comparison to 111In-DTPAOC (Octreoscan), gallium-labelled DOTATOC shows better binding affinity to human somatostatin receptor subtype 2 and improved pharmacology in vivo [1, 2]. Especially if 68Ga-DOTATOC and PET/CT are applied, somatostatin receptor-expressing tumour tissue is excellently visualised. However, SPECT is still a more widely available imaging method. Here we present the first visualisation of a human somatostatin receptor-expressing tumour with 67Ga-DOTATOC SPECT/CT.

A 65-year-old man with known mesenteric lymph node metastases of a surgically removed carcinoid in the small bowel received 180 MBq of 111In-DTPAOC and, 1 week later, 230 MBq of 67Ga-DOTATOC (50 MBq/μg specific activity). All metastases detected with 111In-DTPAOC (a) could be visualised with 67Ga-DOTATOC as well. Scans of 67Ga-DOTATOC (SPECT/CT) were performed less than 4 h post injection to generate excellent images of the mesenteric manifestations (b), with a higher tumour to background ratio compared to that on 111In-DTPAOC images. The presence of only faint renal 67Ga-DOTATOC uptake constitutes a further favourable characteristic of this radiolabelled peptide.

Copyright information

© Springer-Verlag 2005